Boston Biomedical Helps AtriCure (ATRC) 's Synergy Ablation System Win a Recommendation from FDA Expert Advisors
10/28/2011 10:37:44 AM
NORTHBOROUGH, Mass.--(BUSINESS WIRE)--Boston Biomedical Associates today announced that AtriCure, Inc., a medical device company and a leader in cardiac surgical ablation systems and devices for the exclusion of the left atrial appendage, received a vote of approval support from the Circulatory System Panel of the U.S. Food and Drug Administration (FDA) for the AtriCure Synergy Ablation System. The panel voted in favor of FDA approval of the system for the treatment of persistent and longstanding persistent atrial fibrillation during open-heart concomitant surgical procedures. This marks the first time FDA’s expert panel has voted to recommend a surgical ablation system to treat atrial fibrillation.